Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $50
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $38 to $50.
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $38 to $50.